<div class="infobox">
<div class="infobox-header">IQVIA Holdings</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>IQV (NYSE)</td></tr>
<tr><th>Headquarters</th><td>Durham, North Carolina, USA</td></tr>
<tr><th>Founded</th><td>1982 (as IMS Health), merged 2016</td></tr>
<tr><th>Revenue</th><td>$7.4B (2024)</td></tr>
<tr><th>Employees</th><td>90,000+</td></tr>
<tr><th>Market Cap</th><td>~$38B</td></tr>
</table>
</div>
</div>
<div class="infobox">
<div class="infobox-header">IQVIA Holdings</div>
<div class="infobox-content">
<table>
<tr><th>Ticker</th><td>IQV (NYSE)</td></tr>
<tr><th>Headquarters</th><td>Durham, North Carolina, USA</td></tr>
<tr><th>Founded</th><td>1982 (as IMS Health), merged 2016</td></tr>
<tr><th>Revenue</th><td>$7.4B (2024)</td></tr>
<tr><th>Employees</th><td>90,000+</td></tr>
<tr><th>Market Cap</th><td>~$38B</td></tr>
</table>
</div>
</div>
IQVIA Holdings is a leading global provider of healthcare data, analytics, and real-world evidence solutions. The company was formed through the merger of IMS Health and Quintiles IMS in 2016, creating one of the world's largest healthcare intelligence platforms["@iqvia"]. With over four decades of experience in healthcare analytics, IQVIA serves pharmaceutical companies, biotechnology firms, medical device manufacturers, contract research organizations (CROs), and healthcare providers worldwide.
The company's significance to neurodegenerative disease research, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), cannot be overstated. As the global burden of these conditions continues to grow—with an estimated 55 million people living with dementia worldwide and this number projected to rise to 139 million by 2050—IQVIA's real-world evidence capabilities have become essential for understanding disease progression, treatment patterns, and clinical outcomes["1"].
IMS Health was founded in 1982 as Intercontinental Marketing Services, originally focusing on pharmaceutical sales tracking in the United States. Over the subsequent three decades, IMS evolved into the leading provider of healthcare market intelligence, collecting prescription data, sales figures, and promotional activity information from pharmacies, hospitals, and physicians worldwide. By 2015, IMS Health held data from over 45 billion healthcare transactions annually and served 90% of the world's top 50 pharmaceutical companies[@iqvia].
The company's evolution paralleled the growth of evidence-based medicine. In the 1990s, IMS expanded from basic sales tracking to include physician-level prescribing data, enabling pharmaceutical companies to understand prescribing patterns and optimize their marketing strategies. The early 2000s saw the development of electronic prescribing databases and the integration of medical claims data, providing a more complete picture of patient care.
The 2016 merger between IMS Health and Quintiles IMS created IQVIA, combining IMS's data collection capabilities with Quintiles' clinical trial expertise. This merger was transformative for the healthcare analytics industry, creating an end-to-end platform that could support drug development from early-phase research through post-market surveillance. The combined entity gained access to over 800 million patient records, enabling longitudinal analyses that were previously impossible[2].
Real-world evidence (RWE) has become increasingly critical in drug development, particularly for neurodegenerative diseases where clinical trials are complicated by long disease durations, heterogeneous patient populations, and the need for biomarkers that can track disease progression. IQVIA's RWE platform addresses these challenges through comprehensive data assets and sophisticated analytics capabilities[@iqviarwe].
IQVIA maintains one of the world's largest repositories of healthcare data:
| Data Source | Coverage | Relevance to Neurodegeneration |
|-------------|----------|--------------------------------|
| EHR Data | 800M+ patient records | Longitudinal disease progression tracking |
| Prescription Data | 15B+ transactions annually | Treatment pattern analysis |
| Medical Claims | 150M+ patients annually | Healthcare utilization and costs |
| Specialty Databases | Oncology, rare disease, neurology | Disease-specific insights |
| Patient Registries | 200+ condition-specific | Natural history studies |
| Death Records | 45+ countries | Mortality analysis |
The EHR data infrastructure is particularly valuable for [Alzheimer's disease](/diseases/alzheimers-disease) research. Unlike randomized controlled trials that select for homogeneous patient populations, real-world EHR data captures the full spectrum of patients—including those with comorbidities, polypharmacy, and varying disease severities—that clinicians actually encounter[3]. This diversity is essential for understanding how treatments perform in heterogeneous real-world populations.
For Alzheimer's disease research, IQVIA provides[@iqvia_ads]:
One of IQVIA's most valuable capabilities for AD research is the ability to track patient progression from mild cognitive impairment (MCI) to Alzheimer's disease over extended time periods. Using linked EHR and claims data, researchers can identify the sequence of diagnostic events, treatment initiation patterns, and healthcare utilization changes that characterize disease progression[4]. This longitudinal perspective is critical for:
IQVIA's analytics platform supports sophisticated modeling of cognitive decline using real-world data sources. By combining neuropsychological test results from EHR systems with clinical notes processed through natural language processing, the company can generate progression models that capture the heterogeneity of AD trajectories[5]. Key modeling capabilities include:
The validation of emerging biomarkers for AD diagnosis and progression monitoring represents a critical unmet need in the field. IQVIA's real-world datasets provide the scale and diversity necessary for robust biomarker validation studies[6]. The company has supported validation efforts for:
Understanding how AD and PD patients are treated in routine clinical practice is essential for drug development and health economics research. IQVIA's treatment pattern analyses have revealed important insights[7]:
The economic burden of neurodegenerative diseases is substantial, with annual costs in the United States alone exceeding $300 billion for AD and $50 billion for PD. IQVIA's healthcare resource utilization data enables detailed analysis of[8]:
IQVIA's patient-level data enables sophisticated clinical trial feasibility assessments that go beyond simple patient counting[9]. For AD and PD trials, this includes:
IQVIA's clinical trial capabilities span the entire drug development continuum, from early-phase proof-of-concept through late-phase registration trials and post-market commitment studies.
The traditional approach to protocol feasibility relies on investigator surveys and limited database queries. IQVIA's approach uses large-scale patient-level data to simulate eligibility criteria against actual patient populations[10]. This enables sponsors to:
IQVIA's site selection platform integrates historical site performance data, patient population analytics, and competitive landscape information to identify optimal trial sites. For neurodegenerative disease trials, this includes:
Traditional patient recruitment relies on physician referrals, advertising, and site outreach. IQVIA's approach leverages EHR data to enable[11]:
Real-time enrollment analytics enable proactive trial management. IQVIA's platform provides:
The COVID- pandemic accelerated the adoption of decentralized trial designs, and IQVIA has developed comprehensive capabilities for hybrid and fully virtual trial execution[12].
IQVIA's virtual trial platform enables:
Connected device integration enables home-based data collection that was previously only possible in academic medical centers[13]:
Electronic patient-reported outcomes have become essential for capturing patient-centric endpoints in neurodegenerative disease trials:
IQVIA has invested heavily in artificial intelligence and machine learning capabilities to extract value from its vast data assets[14].
The company's AI platform provides:
Unstructured clinical text represents a vast source of untapped information. IQVIA's NLP capabilities enable[15]:
Predictive models for disease progression and treatment response are essential for precision medicine approaches[16]:
IQVIA's technology infrastructure provides the foundation for its analytics capabilities:
| Platform | Function | Application |
|----------|----------|-------------|
| Discover | Analytics workspace | Ad hoc analysis and visualization |
| Orchestrate | Clinical operations | Trial management and execution |
| Intelligence | Real-time dashboards | Performance monitoring |
| Patient Cloud | Data integration | Multi-source data harmonization |
| NOVA | Advanced analytics | ML model development and deployment |
IQVIA operates in a competitive landscape with several significant players:
| Competitor | Primary Strength | IQVIA Differentiation |
|------------|-----------------|----------------------|
| Optum | Integrated payer data | Broader pharma/biotech focus |
| Syneos Health | Full-service CRO | Superior data assets |
| Cegedim | European market presence | Global coverage |
| Real-Life Scientific | Academic partnerships | Scale and commercial orientation |
| Health Catalyst | Hospital system data | Life sciences focus |
| TriNetX | Academic research network | Enterprise analytics depth |
IQVIA's strategic priorities reflect market opportunities and competitive positioning:
| Metric | 2024 | 2023 | 2022 | Change 2023-24 |
|--------|------|------|------|----------------|
| Revenue | $7.4B | $6.9B | $6.4B | +7.2% |
| Adjusted EBITDA | $2.2B | $2.0B | $1.8B | +10% |
| Operating Margin | 18.5% | 17.8% | 17.1% | +0.7pp |
| RWE Revenue | $1.8B | $1.6B | $1.4B | +12.5% |
The growth in RWE revenue reflects increasing demand from pharmaceutical sponsors seeking to leverage real-world data for regulatory submissions, health technology assessment, and medical affairs applications.
IQVIA's data and analytics capabilities align with NeuroWiki's mission to build a comprehensive mechanistic knowledge base for neurodegenerative diseases: